Immunology / Virology & Vaccines

#AstraZeneca #Clinical trials #Covid-19 #Immunology / Virology & Vaccines

SK bioscience and GSK start trial of Covid-19 vaccine 

SK bioscience (SK) and GlaxoSmithKline (GSK) have initiated a Phase III clinical study of SK’s Covid-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase I/II results.  The randomised, active-controlled global trial will enrol around 4,000 participants from a range of countries and will aim to… Read More

#News

#Autoimmune disease #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Moderna #Pfizer

NIH studies Covid-19 vaccine dose for people with autoimmune disease 

The National Institutes of Health (NIH) has begun a clinical trial to assess the antibody response to an extra dose of an authorised or approved Covid-19 vaccine in people with autoimmune disease who did not respond to an original Covid-19 vaccine regimen.   The trial will also investigate whether pausing… Read More

#Covid-19 #News #Trending News

#Comirnaty #Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #Pfizer

This week in drug discovery (23-27 August) 

News round-up by DDW’s Megan Thomas for 23-27 August  The Covid-19 pandemic has undoubtedly put virology back on the drug discovery map and this week, DDW’s Megan Thomas has rounded up five stories which show updates and advancements in the fight against the virus.  … Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Moderna

Japan suspends 1.6 million Moderna doses over contamination fears 

Japan has suspended the use of around 1.63 million doses of the Moderna vaccine due to contamination, which the health ministry confirmed resulted from “foreign materials” in an unused batch of roughly 560,000 vials, according to BBC reports.   According to the news site, Takeda Pharmaceutical, which sells and distributes… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #Regulatory

Moderna submits BLA to FDA for Covid-19 vaccine 

Moderna has completed the rolling submission process for its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the full licensure of the its Covid-19 vaccine for active immunisation to prevent Covid-19 in individuals 18 years of age and older. As part of the completed BLA submission, Moderna has requested Priority… Read More

#Covid-19 #News #Trending News

#Comirnaty #Covid-19 #FDA #Immunology / Virology & Vaccines #Pfizer #Regulatory

Full FDA approval for Pfizer-BioNTech Covid-19 vaccine 

The US Food and Drug Administration (FDA) has approved the Biologics License Application for the Pfizer-BioNTech Covid-19 vaccine. It will now be marketed as Comirnaty for the prevention of Covid-19 disease in individuals 16 years of age and older.  It is the first COVID-19 vaccine to be granted approval by the FDA.  The vaccine continues to… Read More

#Covid-19 #News #Trending News

#Genomics #Immunology / Virology & Vaccines #Research

University researchers develop novel strategy for tuberculosis vaccine 

Researchers at Purdue University and Houston Methodist Research Institute have created a novel strategy for developing an effective vaccine for a widespread form of tuberculosis.  Mycobacterium tuberculosis (Mtb) is a leading cause of death worldwide, leading to over 1.5 million fatalities annually. Approximately one-third of the global… Read More

#News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Valneva begins submission to MHRA for its Covid-19 vaccine 

Valneva has begun a rolling submission for initial approval of its Covid-19 vaccine candidate, VLA2001, with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. VLA2001 is a whole virus, inactivated, adjuvanted vaccine candidate and is the only vaccine candidate of this type currently in clinical trials… Read More

#Covid-19 #News #Trends & Analysis

#Covid-19 #Immunology / Virology & Vaccines #Moderna #Oncology

Moderna’s Covid-19 vaccine maintains antibodies against variants 

New data has been published on the durability of the Moderna Covid-19 vaccine in generating neutralising antibodies against variants. The manuscript was published in Science.   “We are pleased with these new data showing that people vaccinated with two doses of the Moderna Covid-19 vaccine maintained antibodies through six months, including against variants… Read More

#Covid-19 #News

#Antibodies #Immunology / Virology & Vaccines #Malaria #Monoclonal antibodies

Monoclonal antibody prevents malaria in NIH trial 

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health (NIH) safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria… Read More

#News #Trending News

#Cancer immunotherapy #Cancer research #Clinical trials #Immuno-oncology #Immunology / Virology & Vaccines #Tumour biology

Collaboration to develop a novel cancer immunotherapy  

Terumo Blood and Cell Technologies and PhotonPharma have established a memorandum of understanding (MOU) for collaboration to develop Innocell, a novel tumour specific immunotherapy (a therapeutic vaccine)… Read More

#Cancer Research #News

#Biomanufacturing #Corning Life Sciences #Drug discovery #Immunology / Virology & Vaccines #Life sciences #SARS-CoV-2

Optimising vaccine production through customisation

Listen to this article on the DDW Podcast: An expert’s view by John Yoshi Shyu, Ph.D. Corning Life Sciences. Most vaccines are manufactured using technology devised fifty or more years ago, in manufacturing plants that are sometimes even older. The vaccine production process is continually refreshed by new tools… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Third Covid-19 vaccine approved for immunocompromised

Moderna has announced that the U.S. Food and Drug Administration (FDA) has approved an update to the emergency use authorisation for the Moderna Covid-19 vaccine (mRNA-1273) to include a third dose for immunocompromised individuals. The third dose will available to people 18 years of age or older in the United… Read More

#Covid-19 #News

#Drug design #Immunology / Virology & Vaccines #Lipidomics #Lipids #Metabolomics

Lipidomics in biomedical research: chance and challenges

Listen to this article on the DDW Podcast: Lipids are essential for numerous functions in the human body. They are not only components of cell membranes, extracellular vesicles and hormones, but also store energy, facilitate metabolism, mediate cell signalling pathways, and much more. Afrisha Anderson, a Product Manager at… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Clinical trials #Comment #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

From the editor: Staying focused

The drug discovery sector is amazing, says Lu Rahman. And while we have witnessed that on a global scale throughout the pandemic, we should also recognise some of the equally-outstanding non-Covid related developments that have recently taken place. There is, in my opinion, no better industry to be part of at the… Read More

#Covid-19 #Editor's Choice #Exclusive Content #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines

EC to purchase 200 million doses of Novavax NVX-CoV2373

Novavax has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based Covid-19 vaccine candidate with Matrix-M adjuvant. The agreement covers the purchase of up to 100 million doses of the vaccine with the option for… Read More

#News #Trending News